Updated coverage by Health Alliance Plan in Michigan means that an additional 500,000 lives have access to Paradigm Spine’s coflex® interlaminar stabilization product, a non-fusion motion-preserving implant.
coflex gained FDA premarket approval in late 2012 for the treatment of lumbar spinal stenosis (LSS). The device can be used with a decompression or instead of fusion, and results are supported by 5-year follow-up studies that demonstrated long-term, sustained therapeutic effects vs. use of fusion to treat LSS.
Earlier coverage for coflex, announced at the end of 3Q17, reportedly represented the first private payor positive coverage policy for a novel, proven treatment for LSS.
Updated coverage by Health Alliance Plan in Michigan means that an additional 500,000 lives have access to Paradigm Spine's coflex® interlaminar stabilization product, a non-fusion motion-preserving implant.
coflex gained FDA premarket approval in late 2012 for the treatment of lumbar spinal stenosis (LSS). The device can be used with a...
Updated coverage by Health Alliance Plan in Michigan means that an additional 500,000 lives have access to Paradigm Spine’s coflex® interlaminar stabilization product, a non-fusion motion-preserving implant.
coflex gained FDA premarket approval in late 2012 for the treatment of lumbar spinal stenosis (LSS). The device can be used with a decompression or instead of fusion, and results are supported by 5-year follow-up studies that demonstrated long-term, sustained therapeutic effects vs. use of fusion to treat LSS.
Earlier coverage for coflex, announced at the end of 3Q17, reportedly represented the first private payor positive coverage policy for a novel, proven treatment for LSS.
Copy to clipboard 
